New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
10:15 EDTMDCOThe Medicines Co. gaps down, levels to watch
The stock is down over 14.5% to $24.30 at time of writing, most of the loss coming in the form of a bearish gap. The move lower has sent shares to levels last seen in late 2012/early 2013 at a dip in price that later gave rise to the nearly 2-year run shares had to the upside. This nearly total retracement of gains may indicate further price weakness to come, with next support at $23.07. Resistance is at $25.35.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
07:31 EDTMDCOThe Medicines Co. ALN-PCSsc 'a potential game changer,' says RBC Capital
After examining surveys and speaking with experts, RBC Capital says that the uptake of The Medicines Co's ALN-PCSsc treatment has been strong among anti-PCSK9 patients, reaching 20%-30%. The firm estimates that the company could conservatively generate $9B-$18B in revenue from the drug. It believes that the product is "a potential game changer and valuation driver" for the company. RBC keeps a $46 price target and Outperform rating on the shares.
October 1, 2015
07:05 EDTMDCOMedicines Company says BARDA exercises option on Carbavance pact
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of CARBAVANCE. CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae. The cost-share contract with BARDA was initiated in 2014 and extends over 5 years. The award of this third option brings the total commitment from BARDA to $53.8M. If all options are exercised in the contract, it would bring the total value of the award to approximately $90M.
September 25, 2015
09:01 EDTMDCOThe Medicines Co. receives CHMP positive opinion for Ionsys
Subscribe for More Information
September 22, 2015
07:53 EDTMDCOThe Medicines Co. management to meet with Leerink
Meetings to be held in Boston on September 24-25 hosted by Leerink.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use